
GnRHa therapy every 24 weeks comparable to 12-weekly formulation for CPP
UK study findings indicate that a slow-release formulation of the gonadotropin-releasing hormone analogue triporelin given every 24 weeks is as effective as the standard 12-weekly treatment for central precocious puberty.








